The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding in Company

22 Sep 2017 14:01

RNS Number : 5998R
Silence Therapeutics PLC
22 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Silence Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 2,651,683*

 

HSBC Global Custody Nominee (UK) Limited 651,949*

State Street Nominees Limited 50,617*

Available on Request 7,076*

*denotes direct interest

 

Chase (GA Group) Nominees Limited 119,537

 

Chase Nominees Limited 55,444

 

Vidacos Nominees Limited 156,300

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

20/09/2017

6. Date on which issuer notified (DD/MM/YYYY):

21/09/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.28%

5.28%

69,991,624

Position of previous notification (if

applicable)

6.39%

6.39%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB00B9GTXM62

3,361,325

331,281

4.80%

0.48%

SUBTOTAL 8. A

3,692,606

5.28%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Aviva Investors Holdings Limited

5.27%

5.27%

Aviva Investors Global Services Limited

5.27%

5.27%

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Friends Provident

International Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

 

11. Additional informationxvi

This notification is prompted by a 5% to 4% change at Direct Interest Level (Box 8A)

 

Place of completion

Norwich, England

Date of completion

21 September 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGURABUPMGPP
Date   Source Headline
30th Mar 20167:00 amRNSHolding(s) in Company
22nd Mar 20167:00 amRNSNotice of Results
18th Jan 20167:00 amRNSBoard changes
12th Nov 20157:00 amRNSBoard appointment
30th Oct 20152:32 pmRNSLicensee's drug to commence Ph 2/Ph 3 trials
29th Sep 20157:00 amRNSInterim Results
22nd Sep 20157:19 amRNSBoard Change and Notice of Results
30th Jul 20157:01 amRNSInterim Board Change
1st Jun 201511:42 amRNSResult of AGM
1st Jun 20157:00 amRNSAGM statement and clinical trial interim analysis
14th May 20159:55 amRNSReplacement: Holding(s) in Company
14th May 20157:00 amRNSClinical trial update
12th May 201510:19 amRNSHolding(s) in Company
11th May 20155:31 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 20153:07 pmRNSHolding(s) in Company
11th May 201511:29 amRNSHolding(s) in Company
11th May 201510:50 amRNSHolding(s) in Company
11th May 201510:06 amRNSNotice of AGM
8th May 20155:21 pmRNSHolding(s) in Company
1st May 201510:32 amRNSResult of General Meeting and Additional Listing
16th Apr 20155:48 pmRNSAdditional Listing
8th Apr 201511:33 amRNSFundraising update
2nd Apr 20152:34 pmRNSPreliminary results
2nd Apr 20152:34 pmRNSConditional fundraising of approximately £40m
23rd Mar 20157:00 amRNSClinical trial update
16th Feb 20157:00 amRNSPresentation at RNA Therapeutics conference
12th Feb 20157:00 amRNSSuccessful European patent appeal
27th Jan 20157:00 amRNSGrant of share options
5th Jan 20157:00 amRNSBoard Changes
15th Dec 20147:00 amRNSBoard appointment
1st Dec 20147:00 amRNSTrading update and capital markets presentation
1st Dec 20147:00 amRNSTechnology breakthrough
18th Nov 20147:00 amRNSPublication of study data
3rd Nov 201410:26 amRNSAdditional Listing
22nd Oct 20145:44 pmRNSNotification of Major Interest in Shares
23rd Sep 201411:41 amRNSAdditional Listing
16th Sep 20147:00 amRNSHalf year results
2nd Sep 20149:05 amRNSBoard change
27th Aug 20143:38 pmRNSNotice of Results
5th Aug 20147:00 amRNSPublication of pre-clinical study data
30th Jul 20147:00 amRNSLicensee confirms favourable trial outcome
18th Jul 20144:40 pmRNSSecond Price Monitoring Extn
18th Jul 20144:35 pmRNSPrice Monitoring Extension
17th Jul 20145:01 pmRNSNotification of major interest in shares
16th Jul 20147:00 amRNSCompletion of recruitment for phase 2a trial
9th Jul 20144:40 pmRNSSecond Price Monitoring Extn
9th Jul 20144:35 pmRNSPrice Monitoring Extension
3rd Jul 20144:35 pmRNSPrice Monitoring Extension
27th Jun 20144:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.